Table 2. CTA-specific T-cell responses during AZA treatment, direct ex vivo, in % of CD8 cells.

Patient no.	Specificity	Cycle no.1	Cycle no.3	Cycle no.5	Cycle no. 8	Cycle no.9	Cycle no. 10
AZA 1	SART- 3 WLE	0.019	ND	0.025	ND	ND	ND
	SART- 3 QIR	0.052		0.037
	Sp17 ILD	0.038		0.050
AZA 2	MAGE-A2 LVH	0.072	0.065	0.041	ND	0.050	ND
	MAGE-A2 KMV	0.020	0.018	0.012		0.019
	TAG-1 SLG	0.036	0.056	0.038		0.059
AZA 4	MAGE-A2 LVH	0.080	0.086	0.020	ND	ND	ND
	MAGE-A2 LVQ	0.060	0.002	0.001
	NY-ESO-1 QLS	0.012	0.004	0.005
AZA 5	MAGE-A1 EAD	0.001	0.213	0.161	0.031	ND	0.057
AZA 12	MAGE-A2 LVH	0.031	0.030	ND	ND	ND	ND
	MAGE-A2 KMV	0.026	0.015
	CDCA1 KLA	0.007	0.003
	TAG-1 SLG	0.019	0.044
	NY-ESO-1 SLL	0.007	0.010
	MAGE-A1 EAD	0.003	0.265
AZA 16	MAGE-A2 LVH	0.042	0.100	0.059	ND	ND	ND
	MAGE-A2 KMV	0.013	0.025	0.009
	TAG-1 SLG	0.023	0.042	0.068
	GnTV VLP	0.002	0.001	0.001

Abbreviation: ND, not determined.